tbuckley/cabot-search huggingface dataset:
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Authors: P. Merle, A.S. Kulkarni, B.-Y. Ryoo, A.-L. Cheng, M. Kudo, M. Bouattour, H.Y. Lim, V. Breder, J. Edeline, Y. Chao, S. Ogasawara, T. Yau, M. Garrido, S. Chan, B. Daniele, J. Norquist, E. Chen, A.B. Siegel, A.X. Zhu, R.S. Finn
Journal: Annals of Oncology (2019)
CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Authors: I. Compter, D. Eekers, A. Hoeben, K. Rouschop, B.J. Reymen, L. Ackermans, J. Beckervordersantforth, N. Bauer, M. Anten, P. Wesseling, A. Postma, D. De Ruysscher, P. Lambin
Journal: Annals of Oncology (2019)
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
Authors: Gang An, Yuting Yan, Yan Xu, Xuehan Mao, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Zengjun Li, Shuhua Yi, Rui Lv, Shuhui Deng, Weiwei Sui, Mingwei Fu, Mu Hao, Wenyang Huang, Dehui Zou, Yaozhong Zhao, Chenglu Yuan, Xin Du, Jianxiang Wang, Tao Cheng, Yu-Tzu Tai, Nikhil C. Munshi, Lugui Qiu
Journal: Leukemia (2019)
A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer
Authors: D.M. Gershenson, A. Miller, W. Brady, J. Paul, K. Carty, W. Rodgers, D. Millan, R.L. Coleman, K.N. Moore, S. Banerjee, K. Connolly, A.A. Secord, D.M. O’Malley, O. Dorigo, S. Gaillard, H. Gabra, P. Hanjani, H. Huang, L. Wenzel, C. Gourley
Journal: Annals of Oncology (2019)
MIPI as a superior prognostic tool in mantle cell lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Authors: F. Macedo, A.R. Monteiro, D. Coelho, D. Luis, R. Guilherme, M. Gomes, L. Ribeiro
Journal: Annals of Oncology (2019)
Treosulfan/Fludarabine - a Low Toxicity but Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.
Authors: Jerzy Holowiecki, Sebastian Giebel, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Iwona Wylezol, Tomasz Kruzel, Miroslaw Markiewicz
Journal: Blood (2004)
KRAS, BRAF, PIK3CA, and human papilloma virus (HPV) status in squamous cell anal carcinoma (SCAC).
Authors: Andrea Casadei Gardini, Laura Capelli, Paola Ulivi, Massimo Giannini, Eva Freier, Stefano Tamberi, Alessandro Passardi, Paola Rosetti, Daniele Calistri, Luca Saragoni, Maurizio Puccetti, Martina Valgiusti, Dino Amadori, Giovanni Luca Frassineti
Journal: Journal of Clinical Oncology (2013)

e15055 Background: In literature three studies have described KRAS status in SCAC: they analyzed 139 patients, only 1, 4% were mutated. In this study we analyzed BRAF and PIK3CA status. The evaluation of these two genes is important for predicting the response to anti-EGFR drugs. There is one study that values the positivity of HPV in SCAC. This study with few patients shows that the positivity of HPV16 is predictive for improvement of progression free survival (PFS). Methods: 79 patients were treated for anal cancer at the Oncology center of Forlì, Ravenna and Faenza in the last ten years. Up to now we analyzed 29 patients (9 with relapse of disease). DNA was extracted from paraffin-embedded sections and KRAS, BRAF and PIK3CA gene status were assessed by Pyrosequencing methodology, using 3 different kits: anti-EGFR MoAb response (KRAS status), anti-EGFR MoAb response (BRAF status), and anti- EGFR MoAb response (PIK3CA status) (Diatech, Jesi, Ancona, Italy). Reactions were run on a PyroMark Q96 ID (Qiagen). The presence and genotyping of Human Papilloma Virus (HPV) were assessed using the AMPLIQUALITY HPV-HS Bio and AMPLIQUALITY HPV-Type (AB ANALITICA, Padova, Italy) kit. Results: KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene resulted mutated in 9 of 31 cases (28.1%). In particular, 7 mutations occurred in exon 9 (4 E454K and 3 E542K) and 2 in exon 20 (H1047R and H1047L) of the PIK3CA gene. Patients without relapse of disease were positive in 94% of cases for HPV16 and in 40% for mutation of PIK3CA. Patients with relapse of disease were positive in 70% of cases for HPV16 and 37,5% for mutation of PIK3CA. Conclusions: KRAS and BRAF genes were wild type in 100% of cases. This study demonstrates that the SCAC could potentially respond to an anti-EGFR drug.The mutation of PIK3CA does not seem to be predictive for response to treatment. Positivity for HPV16 seems predictive for PFS and overall survival. Furthermore, the study shows that PIK3CA mutation may contribute to carcinogenesis in some cases of this tumor. In addition, patients with a mutation of PI3K could have benefit from specific drugs that inhibit this kinase.
Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)
Authors: C.R. Zurth, K. Fizazi, R. Fricke, H. Gieschen, K. Graudenz, M. Koskinen, B.A. Ploeger, O. Prien, M.R. Smith, T. Tammela, N.D. Shore
Journal: Annals of Oncology (2019)
Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System: Still a Great Need to “EMPROVE”
Authors: Avinash Jain, Saurabh Mittal, Pawan Tiwari, Vijay Hadda, Karan Madan, Anant Mohan
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

To the Editor:We read with keen interest the results of a randomized controlled trial of the Spiration Valve System in patients with severe emphysema by Criner and colleagues (1).We congratulate the authors for presenting a well-designed study on an important clinical question.It has been previously reported that use of endobronchial valves in severe emphysema leads to improvement in FEV 1 compared with placebo, similar to the results found in the present study (2).However, some important points regarding the reported results need careful consideration and further discussion.Although the authors report significant improvement in FEV 1 compared with baseline on 6-month follow-up in the valve group, the overall responder rate is only 37%; that is, only approximately one-third of all patients who received the valve actually demonstrated benefit in airflow.Similarly, although the patient-centered outcomes (i.e., dyspnea and quality of life) improved in the valve group, they did so in only 53% and 54% of subjects, respectively, at 6 months.We feel that this response rate is extremely low by any standard, especially considering the high cost and potential complications associated with valve placement.Therefore, it would be desirable to interpret these results in the proper perspective, based on cost benefit.Considering the patient population in which endobronchial valve therapy is being considered (i.e., those with severe airflow limitation, limited exercise capacity, and receiving long-term oxygen therapy), it may be worthwhile to identify predictors of nonresponse in the endobronchial valve therapy group in an attempt to identify patients most likely to derive benefit from this intervention.This may have important implications for rationalizing clinical practice of emphysema management.
Tumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases
Authors: A. Steindl, E.S. Bergen, D. Alpar, B. Gatterbauer, K. Dieckmann, G. Widhalm, J.A. Hainfellner, M. Schmidinger, C. Bock, L. Müllauer, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2019)
Therapeutic Compliance and Efficacy of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment of Low Risk Diffuse Large B-Cell Lymphoma Patients: Preliminary Results of An Open-Label Clinical Trial in Spain
Authors: Eva Gonzalez-Barca, Miguel Canales, Antonio Salar, Secundino Ferrer, Joan Bargay, S. Grande, Santiago Gardella, María Jesús Vidal, Albert Oriol, A. López, J. García, Jl Bello, Fj Tomás, Javier Briones, Dolores Caballero
Journal: Blood (2008)
Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Authors: F. Griesinger, W.E.E. Eberhardt, H.-R. Bruch, J. Rauh, E. von der Heyde, N.W. Marschner, M. Jänicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, P. Sadjadian, M. Metzenmacher, W. Gleiber, M. Sebastian, M. Thomas
Journal: Annals of Oncology (2019)
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Authors: B. Pellegrino, A. Llop-Guevara, F. Pedretti, C. Cruz, M. Castroviejo, A. Cedro-Tanda, R. Fasani, F. Mateo, A. Musolino, M.A. Pujana, P.G. Nuciforo, A. Gros, J. Balmana, M.J. O’Connor, V. Serra Elizalde
Journal: Annals of Oncology (2019)
Abstract 15434: “Supranormal” Diastolic Function in Athletes is Related to Left Atrial Deformation
Authors: Maria Florescu, Diana Mihalcea, Lucia Stefania Magda, Oana Aurelia Enescu, Berenice Maria Suran, Raluca Mincu, Mircea Cinteza, Dragos Vinereanu
Journal: Circulation (2011)

“Supranormal” diastolic function in athletes was demonstrated previously, but data on LA function is lacking. Our aim was to investigate the relation of the changes in LA deformation assessed by 2D...
Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Authors: Y. Loriot, C.N. Sternberg, D. Castellano Gauna, H. Dumez, R. Huddart, K.M. Vianna, T. Alonso Gordoa, I.A. Skoneczna, A. Fay, C.S.P. Sacco, F. Nole, F. Massari, B. Brasiuniene, P. Maroto, S.F. Oosting, S. Fear, F. Di Nucci, S. De Ducla, E. Choy
Journal: Annals of Oncology (2019)
Mitochondrial Dynamics and Its Involvement in Disease
Authors: David C. Chan
Journal: Annual Review of Pathology Mechanisms of Disease (2019)

The dynamic properties of mitochondria-including their fusion, fission, and degradation-are critical for their optimal function in energy generation. The interplay of fusion and fission confers widespread benefits on mitochondria, including efficient transport, increased homogenization of the mitochondrial population, and efficient oxidative phosphorylation. These benefits arise through control of morphology, content exchange, equitable inheritance of mitochondria, maintenance of high-quality mitochondrial DNA, and segregation of damaged mitochondria for degradation. The key components of the machinery mediating mitochondrial fusion and fission belong to the dynamin family of GTPases that utilize GTP hydrolysis to drive mechanical work on biological membranes. Defects in this machinery cause a range of diseases that especially affect the nervous system. In addition, several common diseases, including neurodegenerative diseases and cancer, strongly affect mitochondrial dynamics.
PS-001-Roles of CC chemokine receptor 9 in the progression and carcinogenesis of murine non-alcoholic steatohepatitis
Authors: Rei Morikawa, Nobuhiro Nakamoto, Takeru Amiya, Po-Sung Chu, Nobuhito Taniki, Hirotoshi Ebinuma, Takanori Kanai
Journal: Journal of Hepatology (2019)
Bevacizumab for children with relapsed &amp; refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial
Authors: L. Moreno, V. Moroz, C. Owens, D. Valteau-Couanet, M. Gambart, V. Castel, N. van Eijkelenburg, A. Castellano, K. Nysom, N. Gerber, G. Laureys, R. Ladenstein, E. Thebaud, D. Murphy, B. Morland, S. Vaidya, M. Elliott, A.D. Pearson, K. Wheatley
Journal: Annals of Oncology (2019)
Cases in Precision Medicine: Should You Participate in a Study Involving Genomic Sequencing of Your Patients?
Authors: Paul S. Appelbaum, Deborah F. Stiles, Wendy Chung
Journal: Annals of Internal Medicine (2019)

Internists and other physicians may be asked to participate in research studies that include genomic screening of their patients. Because genomic studies can identify many variants with potential clinical or personal implications, physicians should carefully consider the effect of participation on their patients, as well as the time and effort needed for the physicians to interpret the results and decide how best to use the information. Among the questions they will need to explore is whether testing will be done in a laboratory that is certified under the Clinical Laboratory Improvement Amendments and authorized to generate results for clinical purposes. Physicians should also determine which results will be returned and how these results are likely to affect their patients. Consent must be obtained from patients for return of results, and physicians may want to use the various informational tools that are available to help their patients through the process of deciding which results to receive. Given the complexity of genomic results, including variable penetrance and possible preventive interventions, the research study should support physicians in understanding the results and their implications for patients. Physicians should be prepared to communicate results in a manner that facilitates patients' understanding of the findings and their implications, using a communication process tailored to the needs of the individual patient. Engaging genetic counselors in helping patients understand the implications of genomic findings can be helpful because of their scientific understanding of genetic disorders, experience in dealing with patients, and training in counseling skills.
Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma
Authors: Z. Ying, T. He, X. Wang, W. Zheng, N. Lin, M. Tu, Y. Xie, L. Ping, C. Zhang, W. Liu, L. Deng, F. Qi, X. Lu, Y. Ding, Y. Song, J. Zhu
Journal: Annals of Oncology (2019)
Abstract 17102: Atherosclerotic Plaques in Mice Experience Greatest Biomechanical Stress Remote From the Fibrous Cap
Authors: Ian C Campbell, Daiana Weiss, John N Oshinski, W. Robert Taylor
Journal: Circulation (2011)

Introduction: Although the atherosclerosis-prone mouse model is widely studied and has contributed much to the current understanding of atherogenesis, rupture of plaques in mice has not been conclusively observed. Consequently, uncertainty of the utility of the mouse model for studying endpoints like plaque rupture pervades in the field. In this study, we investigated the biomechanical likelihood of plaque rupture in mice. Hypothesis: The highest stresses are located away from the fibrous cap of lesions in mice. Methods: We studied acute models of atherosclerosis (15 ApoE-/- and 15 LDLr-/- mice, high-fat diet 8 weeks with simultaneous Angiotensin II osmotic pumps) and a chronic model (15 ApoE-/- mice aged 1 year, regular chow diet). The ascending and descending aortas and brachiocephalic artery were harvested for histological staining of morphology. To preserve in vivo anatomy as accurately as possible, vessels were perfused with a vascular casting compound at each mouse's measured diastolic blood pressure and then embedded in methyl methacrylate resin blocks, which minimize sectioning artifacts. Histology sections were the input geometry for a lesion-specific finite element analysis (FEA) computer model of solid mechanics within the vessel wall. For comparison, we performed similar FEA simulation on 15 human coronary plaques of the thin-cap fibroatheroma (TCFA) phenotype. Results: In human lesions, highest stresses tended to be located on the fibrous cap or shoulders of the plaque, consistent with current understanding of plaque rupture. However, in mouse plaque simulations, the highest stresses and strains were located away from the lesions on the thin plaque-free wall. Conclusion: The characteristic difference in peak stress location explains the lack of plaque rupture in mice. This study demonstrates that local mechanical strains in the fibrous cap of murine atherosclerotic lesions are insufficient to cause plaque rupture, in contrast to human lesions.
Sample Size Estimates for Cluster-Randomized Trials in Hospital Infection Control and Antimicrobial Stewardship
Authors: Natalia Blanco, Anthony D. Harris, Laurence S. Magder, John A. Jernigan, Sujan C. Reddy, Justin O’Hagan, Kelly M. Hatfield, Lisa Pineles, Eli Perencevich, Lyndsay M. O’Hara
Journal: JAMA Network Open (2019)

<h3>Importance</h3> An important step in designing, executing, and evaluating cluster-randomized trials (CRTs) is understanding the correlation and thus nonindependence that exists among individuals in a cluster. In hospital epidemiology, there is a shortage of CRTs that have published their intraclass correlation coefficient or coefficient of variation (CV), making prospective sample size calculations difficult for investigators. <h3>Objectives</h3> To estimate the number of hospitals needed to power parallel CRTs of interventions to reduce health care–associated infection outcomes and to demonstrate how different parameters such as CV and expected effect size are associated with the sample size estimates in practice. <h3>Design, Setting, and Participants</h3> This longitudinal cohort study estimated parameters for sample size calculations using national rates developed by the Centers for Disease Control and Prevention for methicillin-resistant<i>Staphylococcus aureus</i>(MRSA) bacteremia, central-line–associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), and<i>Clostridium difficile</i>infections (CDI) from 2016. For MRSA and vancomycin-resistant enterococci (VRE) acquisition, outcomes were estimated using data from 2012 from the Benefits of Universal Glove and Gown study. Data were collected from June 2017 through September 2018 and analyzed from September 2018 through January 2019. <h3>Main Outcomes and Measures</h3> Calculated number of clusters needed for adequate power to detect an intervention effect using a 2-group parallel CRT. <h3>Results</h3> To study an intervention with a 30% decrease in daily rates, 73 total clusters were needed (37 in the intervention group and 36 in the control group) for MRSA bacteremia, 82 for CAUTI, 60 for CLABSI, and 31 for CDI. If a 10% decrease in rates was expected, 768 clusters were needed for MRSA bacteremia, 875 for CAUTI, 631 for CLABSI, and 329 for CDI. For MRSA or VRE acquisition, 50 or 40 total clusters, respectively, were required to observe a 30% decrease, whereas 540 or 426 clusters, respectively, were required to detect a 10% decrease. <h3>Conclusions and Relevance</h3> This study suggests that large sample sizes are needed to appropriately power parallel CRTs targeting infection prevention outcomes. Sample sizes are most associated with expected effect size and CV of hospital rates.
Novel Subtypes Based on Microenvironment Immune Signature Provides Prognostic Stratification and Therapeutic Strategy in Peripheral T-Cell Lymphoma
Authors: Takeshi Sugio, Kohta Miyawaki, Kensuke Sasaki, Koji Kato, Hiroaki Miyoshi, Koichi Ohshima, Takahiro Maeda, Koichi Akashi
Journal: Blood (2017)
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura
Authors: Elie Azoulay, Philippe R. Bauer, Eric Mariotte, Lene Russell, Paul Knoebl, Ignacio Martin-Loeches, Frédéric Pène, Kathryn Puxty, Pedro Povoa, Andreas Barratt-Due, Jose Garnacho-Montero, Julia Wendon, Laveena Munshi, Dominique Benoit, Michael von Bergwelt-Baildon, Marco Maggiorini, Paul Coppo, Spero Cataland, Agnès Veyradier, Andry Van de Louw
Journal: Intensive Care Medicine (2019)
Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis
Authors: Davine Hofste op Bruinink, Hoogenboezem Remco, Mathijs A. Sanders, Christopher P Wardell, Cody Ashby, Eric M.J. Bindels, Claudia Erpelinck-Verschueren, Paulette van Strien, Jasper Koenders, François G. Kavelaars, Jie He, Mark Bailey, Tariq I Mughal, Kristine Misund, Berna Beverloo, Bronno van der Holt, Ivo Touw, Anders Waage, Hervé Avet-Loiseau, Graham H Jackson, Gareth J Morgan, Brian A Walker, Pieter Sonneveld
Journal: Blood (2016)
Efficacy of enzalutamide in hormone-sensitive metastatic prostate cancer: Clinical utility of 18F-choline PET and whole body MRI
Authors: S. Osanto, C. Alvarez, H. Bloem, T. van der Hulle, M. Jonker, M. Ozdemir, K. Goossens, M. Wijffelman, R. Pelger, H. Van Poppel, K. Burggraaf
Journal: Annals of Oncology (2019)
Abstract 15885: Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters
Authors: Emily A Fletcher, Carolyn S Lacey, Sachin A Shah
Journal: Circulation (2014)

Introduction: Cases of QT prolongation and other life-threatening arrhythmias have been reported with acute high volume energy drink (ED) usage. While caffeine doses under 400mg are not considered arrhythmogenic, the safety of the other ingredients in EDs need evaluation. This study evaluated the ECG and blood pressure effects of acute high volume ED consumption when compared to caffeine.

Methods: This was a double-blind, controlled, crossover study enrolling young healthy volunteers. Subjects randomly consumed a single 32oz dose of an ED (320 mg caffeine) and a matching caffeinated (320 mg) control drink separated by a 6-day washout period. A standard 12-lead ECG and blood pressure were obtained at baseline, 1, 2, 4, 6 and 24 hours post drink consumption. The intra-group change from baseline in the QTc, QT and PR intervals, QRS duration, systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were evaluated using the paired student’s t-test.

Results: Eighteen subjects (27±4 yrs) were included for analysis. A significant difference in the QTc interval was noted 2 hours post ED consumption when compared to the caffeine arm (0.44±18.4 vs -10.4±14.8 msec; p=0.036). SBP was significantly higher 6 hours post ED consumption when compared to the caffeine arm (4.72±4.67 vs 0.83±6.09 mmHg; p=0.016). A significant increase in HR was evident 2 hours post ED consumption when compared to the caffeine arm (3.39±11.0 vs -0.61±9.13 bpm; p=0.045). There were no time matched intra-group differences with the QT and PR intervals, QRS duration and DBP. The maximum and minimum intra-group change from baseline were no different for all endpoints (all p-values >0.195).

Conclusions: EDs did not reduce 2 hour post dosing QTc interval as observed with caffeine. ED consumption increased SBP and HR by 4 mmHg and 3 bpm, respectively when compared to caffeine. Ingredients other than caffeine in EDs warrant further investigation. The work reported herein was performed under United States Air Force Surgeon General approved Clinical Investigation Number FDG20130042H. The views expressed in this material are those of the authors, and do not reflect the official policy or position of the U.S. Government, the Department of Defense or the Department of the Air Force.
Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
Authors: E. Lai, M. Schirripa, M. Puzzoni, F. Loupakis, P. Ziranu, A. Pretta, R. Giampieri, S. Mariani, N. Liscia, P. Soro, V. Pusceddu, G. Astara, V. Impera, S. Camera, F. Musio, A. Zaniboni, M. Fassan, S. Lonardi, V. Zagonel, M. Scartozzi
Journal: Annals of Oncology (2019)
Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Authors: A. Pender, E. Titmuss, E. Pleasance, K. Fan, H. Pearson, M. Bonakdar, G. Taylor, K. Mungall, R. Moore, J.-M. Lavoie, S. Yip, H. Lim, D. Renouf, S.J. Jones, M.A. Marra, J.J. Laskin
Journal: Annals of Oncology (2019)
Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial
Authors: D.H. Lee, D.-W. Kim, D.R. Camidge, C.J. Langer, R.M. Huber, M. Tiseo, H.L. West, H.J.M. Groen, K.L. Reckamp, M.J. Hochmair, N.B. Leighl, K.H. Hansen, S.N. Gettinger, L. Paz-Ares, E.S. Kim, E.F. Smit, S.-W. Kim, Q. Ni, P. Zhang, M.-J. Ahn
Journal: Annals of Oncology (2019)